

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
24 March 2005 (24.03.2005)

PCT

(10) International Publication Number
WO 2005/026095 A1

(51) International Patent Classification⁷: C07C 51/363, 51/347, 65/21, 67/00, 69/84, 69/92, A61K 31/44, A61P 11/06

(74) Common Representative: RANBAXY LABORATORIES LIMITED; c/o DESHMUKH, Jay, R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(21) International Application Number:
PCT/IB2004/002959

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
13 September 2004 (13.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1145/Del/2003 12 September 2003 (12.09.2003) IN

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): RANBAXY LABORATORIES LIMITED [IN/IN]; 19, Nehru Place, New Delhi, Delhi 110019 (IN).

(72) Inventors; and


(75) Inventors/Applicants (for US only): BOSE, Prosenjit [IN/IN]; House No. A-92, First Floor, Suncity - II, Sohna Road, Gurgaon, Haryana 122001 (IN). SACHDEVA, Yoginder, Pal [IN/IN]; Street No. 2, H. No. 451, Krishna Nagar, Abohar, Ferozepur, Punjab 152116 (IN). RATHORE, Ramendra, Singh [IN/IN]; House No. 4/1, Mohalla - Chobdaran, Farrukhabad, Uttar Pradesh 209625 (IN). KUMAR, Yatendra [IN/IN]; U-26/5, Phase - III, DLF Qutab Enclave, Gurgaon, Haryana 122001 (IN).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR THE PREPARATION OF ROFLUMILAST




(57) Abstract: The present invention relates to a process for the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid of structural Formula I, and to the use of this compound as an intermediate for the preparation of roflumilast.

WO 2005/026095 A1

PROCESS FOR THE PREPARATION OF ROFLUMILAST

Field of the Invention


The field of the invention relates to a process for the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid of Formula I, and to the use of this 5 compound as an intermediate for the preparation of roflumilast.



FORMULA I

Background of the Invention

10 Chemically, roflumilast is 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide of Formula VI, and is known from U.S. Patent No. 5,712,298.



FORMULA VI

15 Roflumilast is an effective phosphodiesterase-4-inhibitor (PDE4-inhibitor), which can be used in the treatment of asthma, inflammation, bronchitis, allergy, osteoporosis, dermatoses and disorders related to immune system, heart and kidney.


U.S. Patent No. 5,712,298 discloses the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid comprising reacting 4-hydroxy-3-cyclopropylmethoxybenzaldehyde with dichlorofluoromethane followed by oxidation.

U.S. Patent No. 6,712,274 discloses the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid comprising reacting dihydroxybenzaldehyde with tertiarybutyl difluorochloroacetate in the presence of lithium carbonate and reacting the obtained 4-difluoromethoxy-3-hydroxy benzaldehyde with cyclopropylmethyl bromide in the presence of potassium carbonate followed by oxidation to yield 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid.

10

Summary of the Invention


In one general aspect there is provided a process for the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid. The process includes reacting the compound of Formula II,



15

FORMULA II

wherein R represents alkyl of C₁-C₆, alkenyl of C₁-C₆, substituted or unsubstituted phenyl, benzhydryl, triphenylmethyl, or substituted or unsubstituted benzyl, with difluoro methylating agent in the presence of a base to obtain compound of Formula III,




20

FORMULA III

wherein R is as defined above; and desterification of the compound of Formula III to obtain the compound of Formula I.

In another general aspect there is provided a process for the preparation of 3-cyclopropylmethoxy-4-hydroxy benzoate of Formula II. The process includes reacting 3,4-dihydroxy benzoate of Formula IV,



5

FORMULA IV

wherein R is as defined above, with cyclopropylmethyl derivative of Formula V,

**FORMULA V**

wherein X is a leaving group, in the presence of a base.

10 In another general aspect there is provided a novel compound, 3-cyclopropylmethoxy-4-hydroxy benzoate of Formula II.

In another general aspect there is provided a novel compound of Formula III.

15 In another general aspect there is provided a process for the preparation of roflumilast. The process includes reacting compound of Formula I with 4-amino-3,5-dichloro pyridine.

In another aspect there is provided a pharmaceutical composition that includes a therapeutically effective amount of roflumilast; and one or more pharmaceutically acceptable carriers, excipients or diluents.

20 The details of one or more embodiments of the inventions are set forth in the description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.

Detailed Description of the Invention

The inventors have developed an efficient process for the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy benzoic acid. The process involves reacting the

compound of Formula II, wherein R represents alkyl of C₁-C₆, alkenyl of C₁-C₆, substituted or unsubstituted phenyl, benzhydryl, triphenylmethyl, or substituted or unsubstituted benzyl, with difluoro methylating agent in the presence of a base to obtain compound of Formula III, wherein R is as defined above; and desterification of the 5 compound of Formula III to obtain the compound of Formula I.

Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, secondary butyl and tert- butyl groups. Examples of alkenyl groups include vinyl, allyl, isopropenyl, pentenyl and hexenyl groups. The substituted phenyl includes phenyl substituted by 1-3 substituents, which are independently bromine, chlorine, fluorine, C₁-10 C₄ alkyl, C₁-C₄ alkoxy, and nitro groups. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy and butoxy groups. The substituted benzyl includes p-nitro benzyl, p-methoxy benzyl, o-nitro benzyl, p-bromo benzyl, and 2,4,6-trimethyl benzyl groups.

The difluoro methylating agent which can be used for preparing 3-15 cyclopropylmethoxy-4-difluoromethoxy benzoic acid of Formula I include difluorochloromethane (Freon-22[®]), alkyl difluorochloroacetate such as methyl difluorochloroacetate, ethyl difluorochloro acetate and tertiarybutyl difluorochloroacetate.

The bases which can be used include organic and inorganic bases. Examples of 20 organic bases include trimethylamine, triethylamine, tributylamine, triisopropylamine, diisopropylethylamine, DBU (1,8-diazabicyclo-[5.4.0]-undec-7-ene), DBN (1,5-diazabicyclo-[4.3.0]-non-5-ene), 4-dimethylamino pyridine and mixtures thereof. Examples of inorganic bases include alkali metal carbonate, bicarbonate, hydroxide and mixtures thereof. Examples of alkali metal carbonates include lithium carbonate, 25 sodium carbonate and potassium carbonate. Examples of alkali metal bicarbonates include sodium bicarbonate and potassium bicarbonate. Examples of alkali metal hydroxides include sodium hydroxide and potassium hydroxide.

The reaction of compound of Formula II with difluoromethylating agent may be carried out in the presence of phase transfer catalyst. Examples of such phase transfer 30 catalysts include quaternary ammonium salts such as tetramethyl ammonium iodide, tetrabutyl ammonium iodide, benzyltributyl ammonium bromide, 1-methylpyridinium iodide, tetramethyl-2-butylammonium chloride, trimethylcyclopropylammonium

chloride, tetrabutylammonium bromide and t-butylethyldimethylammonium bromide; quaternary phosphonium salts such as tributylmethylphosphonium iodide, triethylmethylphosphonium iodide, methyltriphenoxypyrophosphonium iodide, tetrabutyl phosphonium bromide, benzyltriphenyl phosphonium bromide, and tetraphenyl phosphonium chloride.

5 The reaction of compound of Formula II with difluoromethylating agent may be carried out in the presence of a suitable solvent. Suitable solvents are inert organic solvents that do not change under the reaction conditions. Examples of such solvents include alkyl ethers such as diethylether, diisopropylether and dimethoxyethane; nitriles 10 such as acetonitrile and benzonitrile; alcohols such as methanol, ethanol, isopropanol and butanol; ketones such as acetone and methyl isobutyl ketone; chlorinated hydrocarbons such as methylene chloride, ethylene dichloride and carbon tetrachloride; esters such as ethylacetate and isopropylacetate; hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane, heptane and octane; dipolar aprotic solvents such as 15 dimethylsulfoxide and dimethylformamide; cyclic ethers such as dioxane and tetrahydrofuran, and mixtures thereof.

The reaction may be carried out at a temperature of from about 20°C to about 120°C, for example at a temperature of from about 25°C to about 50°C.

20 The compound of Formula III is converted to the compound of Formula I by conventional methods including hydrolysis or hydrogenation, in case R is a benzylic group.

Examples of leaving group X, in the compound of Formula V, include chlorine, bromine, iodine, sulphate and tosylate.

25 The base, phase transfer catalyst and solvent, which may be used for preparing 3-cyclopropylmethoxy-4-hydroxy benzoate of Formula II from compound of Formula IV, can be the same as those which can be used in reaction of compound of Formula II with difluoromethylating agent.

The reaction may be performed at a temperature from about 20°C to about 120°C. In particular, it may be performed at a temperature from about 25°C to 50°C.

30 In general, roflumilast of Formula VI is prepared by reacting an activated derivative of the acid of Formula I, such as acid halide or a reactive ester, with 4-amino-3,5-dichloro pyridine. For example, roflumilast can be prepared by reacting the

corresponding acid chloride of the compound of Formula I with 4-amino-3,5-dichloro pyridine in the presence of sodium hydride in tetrahydrofuran.

The resulting roflumilast may be formulated into ordinary dosage forms such as, for example, tablets, capsules, pills, solutions, etc. In these cases, the medicaments can 5 be prepared by conventional methods with conventional pharmaceutical excipients.

The compositions include dosage forms suitable for oral, buccal, rectal, and parenteral (including subcutaneous, intramuscular, and ophthalmic) administration. The oral dosage forms may include solid dosage forms, like powder, tablets, capsules, suppositories, sachets, troches and lozenges as well as liquid suspensions, emulsions, 10 pastes and elixirs. Parenteral dosage forms may include intravenous infusions, sterile solutions for intramuscular, subcutaneous or intravenous administration, dry powders to be reconstituted with sterile water for parenteral administration, and the like.

The roflumilast can be administered for the treatment the treatment of asthma, inflammation, bronchitis, allergy, osteoporosis, dermatoses and disorders related to 15 immune system, heart and kidney in a warm-blooded animal.

For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.

In the following section embodiments are described by way of examples to 20 illustrate the process of invention. However, these do not limit the scope of the present invention. Variants of these examples would be evident to persons ordinarily skilled in the art.

Example 1: Preparation of 3-Cyclopropylmethoxy-4-hydroxy methyl benzoate

3,4-Dihydroxy methyl benzoate (50 g) was stirred with cyclopropylmethyl 25 bromide (50.2 g) and potassium carbonate (82.1 g) in acetone (350 ml) for 18 hours at 40°C. The reaction mixture was filtered over a hyflo bed followed by concentration of the organic layer.

The crude product was purified over a silica gel column (eluting with 5 % ethyl acetate in hexane) to obtain the title product.

30 Yield: 16 g.

HPLC Purity: 99.5%

Example 2: Preparation of 3-Cyclopropylmethoxy-4-difluoromethoxy benzoic acid

The product obtained from Example 1 (10 g) was subjected to difluoromethylation using difluorochloromethane, 35 % w/w sodium hydroxide aqueous solution (50 ml), tetrabutyl ammonium bromide (5.9 g) in toluene (100 ml) as solvent at 5 20 to 35° C. The resulting product, 3-cyclopropylmethoxy-4-difluoromethoxy methyl benzoate was hydrolyzed *in situ* by adding 50 ml water and heating the reaction mixture to 50 to 55°C. pH of the reaction mixture was adjusted to 3-4 by adding concentrated hydrochloric acid at 20 to 30°C followed by extraction with ethyl acetate (48 ml). The solvent was evaporated under vacuum and the product was collected.

10 Yield: 10 g.

HPLC Purity: 94.0%

Example 3: Preparation of roflumilast

The product obtained from Example 2 (10g) was heated with thionyl chloride (5.8g) and catalytic amount of dimethylformamide (0.5ml) at 80 to 85°C for 1 hour. The 15 solution was evaporated *in vacuo* and the oily residue was dissolved in dry tetrahydrofuran (50 ml). This was added dropwise at 0°C to a suspension prepared from sodium hydride (3.75 g, 60% suspension) and 4-amino-3,5-dichloro pyridine (9.5g) in dry tetrahydrofuran (50 ml) with stirring. The reaction mixture was stirred for 30 minutes and then acidified to pH 2 with hydrochloric acid (1 N). The reaction mixture 20 was extracted with ethyl acetate. The extracted solvent was washed with sodium bicarbonate solution (5%) and water followed by evaporation in vacuum. The residue was dissolved in methanol (45 ml) at 60°C and 5 ml of water was added to get precipitate. The mixture was then cooled to 10°C and filtered to obtain roflumilast.

Yield: 9.2 g


25 Purity: 99%

m.p.: 157-158°C

30 While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are included within the scope of the present invention.


We claim:

1 1. A process for the preparation of 3-cyclopropylmethoxy-4-difluoromethoxy
2 benzoic acid of Formula I,




4 **FORMULA I**

5 the process comprising reacting compound of Formula II,



7 **FORMULA II**

8 wherein R represents alkyl of C₁-C₆, alkenyl of C₁-C₆, substituted or unsubstituted
9 phenyl, benzhydryl, triphenylmethyl, or substituted or unsubstituted benzyl, with
10 difluoro methylating agent in the presence of a base to obtain compound of Formula III,



12 **FORMULA III**

13 wherein R is as defined above; and desterification of the compound of Formula III to
14 obtain the compound of Formula I.

1 2. The process of claim 1, wherein R represents methyl or ethyl.

1 3. The process of claim 1, wherein the difluoromethylating agent comprises one or
2 more of difluorochloromethane (Freon-22[®]) and alkyl difluorochloroacetate.

1 4. The process of claim 3, wherein the alkyl difluorochloroacetate comprises one or
2 more of methyl difluorochloroacetate, ethyl difluorochloroacetate and tertiary butyl
3 difluorochloroacetate.

1 5. The process of claim 1, wherein the base comprises one or more of inorganic and
2 organic bases.

1 6. The process of claim 5, wherein the organic base comprises one or more of
2 trimethylamine, triethylamine, tributylamine, triisopropylamine, diisopropylethylamine,
3 DBU (1,8-diazabicyclo- [5.4.0]-undec-7-ene), DBN (1,5- diazabicyclo-[4.3.0]-non-5-
4 ene), and 4-dimethylamino pyridine.

1 7. The process of claim 5, wherein the inorganic base comprises one or more of
2 alkali metal carbonates, alkali metal bicarbonates and alkali metal hydroxides.

1 8. The process of claim 7, wherein the alkali metal carbonate comprises one or
2 more of lithium carbonate, sodium carbonate and potassium carbonate.

1 9. The process of claim 7, wherein the alkali metal bicarbonate comprises one or
2 both of sodium bicarbonate and potassium bicarbonate.

1 10. The process of claim 7, wherein the alkali metal hydroxide comprises one or
2 both of sodium hydroxide and potassium hydroxide.


1 11. The process of claim 1, wherein the reaction is carried out in the presence of a
2 phase transfer catalyst.

1 12. The process of claim 11, wherein the phase transfer catalyst comprises one or
2 more of quaternary ammonium salts and quaternary phosphonium salts.

1 13. The process of claim 12, wherein the quaternary ammonium salt comprises one
2 or more of tetramethyl ammonium iodide, tetrabutyl ammonium iodide, benzyltributyl
3 ammonium bromide, 1-methylpyridinium iodide, tetramethyl-2-butylammonium
4 chloride, trimethylcyclopropylammonium chloride, tetrabutylammonium bromide, and
5 t-butylethyldimethylammonium bromide.

- 1 14. The process of claim 12, wherein the quaternary phosphonium salt comprises
- 2 one or more of tributylmethyphosphonium iodide, triethylmethylphosphonium iodide,
- 3 methyltriphenoxypyrophosphonium iodide, tetrabutyl phosphonium bromide,
- 4 benzyltriphenyl phosphonium bromide, and tetraphenyl phosphonium chloride.
- 1 15. The process of claim 1, wherein the reaction is carried out in a solvent.
- 1 16. The process of claim 15, wherein the solvent comprises one or more of alkyl
- 2 ethers, alcohols, ketones, chlorinated hydrocarbons, esters, hydrocarbons, dipolar aprotic
- 3 solvents, cyclic ethers, and nitriles.
- 1 17. The process of claim 16, wherein the ether comprises one or more of
- 2 diethylether, diisopropylether and dimethoxyethane.
- 1 18. The process of claim 16, wherein the alcohol comprises one or more of
- 2 methanol, ethanol, isopropanol and butanol.
- 1 19. The process of claim 16, wherein the ketone comprises one or both of acetone
- 2 and methyl isobutyl ketone.
- 1 20. The process of claim 16, wherein the chlorinated hydrocarbon comprises one or
- 2 more of methylene chloride, ethylene dichloride and carbon tetrachloride.
- 1 21. The process of claim 16, wherein the ester comprises one or both of ethylacetate
- 2 and isopropylacetate.
- 1 22. The process of claim 16, wherein the hydrocarbon comprises one or more of
- 2 benzene, xylene, toluene, hexane, cyclohexane, heptane and octane.
- 1 23. The process of claim 16, wherein the dipolar aprotic solvent comprises one or
- 2 both of dimethylsulfoxide, and dimethylformamide.
- 1 24. The process of claim 16, wherein the cyclic ether comprises one or both of
- 2 dioxane, and tetrahydrofuran.
- 1 25. The process of claim 16, wherein the nitrile comprises one or both of acetonitrile
- 2 and benzonitrile.
- 1 26. The process of claim 1, wherein the reaction of compound of Formula II with
- 2 difluoro methylating agent is carried out at temperature of from about 25°C to about
- 3 50°C.

1 27. A process for the preparation of 3-cyclopropylmethoxy-4-hydroxy benzoate of
2 Formula II,



5

6

7

FORMULA II

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894

895

896

897

898

899

900

901

902

903

904

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922

923

924

925

926

927

928

929

930

931

932

933

934

935

936

937

938

939

940

941

942

943

944

945

946

947

948

949

950

951

952

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972

973

974

975

976

977

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993

994

995

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018

1019

1020

1021

1022

1023

1024

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061

1062

1063

1064

1065

1066

1067

1068

1069

1070

1071

1072

1073

1074

1075

1076

1077

1078

1079

1080

1081

1082

1083

1084

1085

1086

1087

1088

1089

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111

1112

1113

1114

1115

1116

1117

1118

1119

1120

1121

1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132

1133

1134

1135

1136

1137

1138

1139

1140

1141

1142

1143

1144

1145

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180

1181

1182

1183

1184

1185

1186

1187

1188

1189

1190

1191

1192

1193

1194

1195

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207

1208

1209

1210

1211

1212

1213

1214

1215

1216

1217

1218

1219

1220

1221

1222

1223

1224

1225

1226

1227

1228

1229

1230

1231

1232

1233

1234

1235

1236

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253

1254

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

1271

1272

1273

1274

1275

1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289

1290

1291

1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306

1307

1308

1309

1310

1311

1312

1313

1314

1315

1316

1317

1318

1319

1320

1321

1322

1323

1324

1325

1326

1327

1328

1329

1330

1331

1332

1333

1334

1335

1336

1337

1338

1339

1340

1341

1342

1343

1344

1345

1346

1347

1348


1349

1350

135

- 1 31. The process of claim 29, wherein the inorganic base comprises one or more of
2 alkali metal carbonates, alkali metal bicarbonates and alkali metal hydroxides.
- 3 32. The process of claim 31, wherein the alkali metal carbonate comprises one or
4 more of lithium carbonate, sodium carbonate and potassium carbonate.
- 1 33. The process of claim 31, wherein the alkali metal bicarbonate comprises one or
2 both of sodium bicarbonate and potassium bicarbonate.
- 1 34. The process of claim 31, wherein the alkali metal hydroxide comprises one or
2 both of sodium hydroxide and potassium hydroxide.
- 1 35. The process of claim 27, wherein the reaction is carried out in the presence of a
2 phase transfer catalyst.
- 1 36. The process of claim 35, wherein the phase transfer catalyst comprises one or
2 more of quaternary ammonium salts and quaternary phosphonium salts.
- 1 37. The process of claim 36, wherein the quaternary ammonium salt comprises one
2 or more of tetramethyl ammonium iodide, tetrabutyl ammonium iodide, benzyltributyl
3 ammonium bromide, 1-methylpyridinium iodide, tetramethyl-2- butylammonium
4 chloride, trimethylcyclopropylammonium chloride, tetrabutylammonium bromide, and
5 t-butylethyldimethylammonium bromide.
- 1 38. The process of claim 36, wherein the quaternary phosphonium salt comprises
2 one or more of tributylmethylphosphonium iodide, triethylmethylphosphonium iodide,
3 methyltriphenoxypyrophosphonium iodide, tetrabutyl phosphonium bromide,
4 benzyltriphenyl phosphonium bromide, and tetraphenyl phosphonium chloride.
- 1 39. The process of claim 27, wherein the reaction is carried out in a solvent.
- 1 40. The process of claim 39, wherein the solvent comprises one or more of alkyl
2 ethers, alcohols, ketones, chlorinated hydrocarbons, esters, hydrocarbons, dipolar aprotic
3 solvents, cyclic ethers, and nitriles.
- 1 41. The process of claim 27, wherein the leaving group X in the compound of
2 Formula V represents chlorine, bromine, iodine, sulphate and tosylate.
- 1 42. The process of claim 27, wherein the reaction of compound of Formula IV with
2 cyclopropylmethyl derivative of Formula V is carried out at temperature of from about
3 25°C to about 50°C.

1 43. The process of claim 1, further comprising reacting an activated derivative of
2 the compound of Formula I with 4-amino-3,5-dichloro pyridine,



3

4 **FORMULA VI**

5 to give a compound of Formula VI.


1 44. The process of claim 43, wherein the activated derivative is acid halide or a
2 reactive ester of the compound of Formula I.

1 45. The process of claim 44, wherein the reaction of activated derivative of the
2 Formula I with 4-amino-3,5-dichloro pyridine is carried out in the presence of sodium
3 hydride in tetrahydrofuran.

1 46. A pharmaceutical composition comprising a therapeutically effective amount of
2 roflumilast obtained by the process of claim 43; and one or more pharmaceutically
3 acceptable carriers, excipients or diluents.

1 47. A method of treating asthma, inflammation, bronchitis, allergy, osteoporosis,
2 dermatoses and disorders related to immune system, heart and kidney in a warm-
3 blooded animal comprising administering a pharmaceutical composition that includes
4 roflumilast prepared by the process of claim 43.

1 48. A compound of Formula II,



4

5


3

FORMULA II

4 wherein R represents alkyl of C₁-C₆, alkenyl of C₁-C₆, substituted or unsubstituted
5 phenyl, benzhydryl, triphenylmethyl, or substituted or unsubstituted benzyl.

1 49. The compound of claim 48, wherein R represents methyl or ethyl.

1 50. A compound of Formula III,



4

5

3

FORMULA III

4 wherein R represents alkyl of C₁-C₆, alkenyl of C₁-C₆, substituted or unsubstituted
5 phenyl, benzhydryl, triphenylmethyl, or substituted or unsubstituted benzyl.

1 51. The compound of claim 50, wherein R represents methyl or ethyl.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IB2004/002959

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07C51/363	C07C51/347	C07C65/21	C07C67/00	C07C69/84
	C07C69/92	A61K31/44	A61P11/06		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2004/033430 A (ALBEMARLE CORPORATION) 22 April 2004 (2004-04-22) page 1, line 6 – line 12; example 3 page 6, line 15 – line 22	46, 47, 50, 51
X	REID P: "ROFLUMILAST" CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 8, August 2002 (2002-08), pages 1165-1170, XP001119630 ISSN: 0967-8298 the whole document	46, 47
A	US 5 712 298 A (AMSCHELER ET AL) 27 January 1998 (1998-01-27) cited in the application column 9 – column 11	1-51

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the International filing date but later than the priority date claimed

- *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 February 2005

Date of mailing of the International search report

23/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Österle, C

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2004/002959

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 47 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Intern

Application No

IB2004/002959

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 2004033430	A	22-04-2004	US WO	6822114 B1 2004033430 A2		23-11-2004 22-04-2004
US 5712298	A	27-01-1998	AT AU AU CA CN CY CZ DE DK WO EP ES FI HK HU JP JP NO NZ PL PT RU SI SK	217612 T 687087 B2 7490794 A 2165192 A1 1126468 A ,C 2389 A 9600001 A3 59410119 D1 706513 T3 9501338 A1 0706513 A1 2176252 T3 956333 A 1011690 A1 73232 A2 8512041 T 3093271 B2 955211 A 271316 A 311820 A1 706513 T 2137754 C1 706513 T1 161795 A3		15-06-2002 19-02-1998 24-01-1995 12-01-1995 10-07-1996 10-09-2004 12-06-1996 20-06-2002 09-09-2002 12-01-1995 17-04-1996 01-12-2002 29-12-1995 11-10-2002 29-07-1996 17-12-1996 03-10-2000 21-12-1995 24-11-1997 18-03-1996 31-10-2002 20-09-1999 31-10-2002 03-07-1996